Oxon Life Science

OXON Epidemiology (operating as Oxon Life Science) is a specialized contract research organization (CRO) that provides real-world evidence (RWE) and pharmacoepidemiology services to the global pharmaceutical and biotech industries. The company focuses on the design and execution of observational studies, safety registries, and post-authorization safety and efficacy studies (PASS/PAES). With a strong academic foundation, OXON offers strategic consultancy to help clients navigate complex regulatory requirements and demonstrate product value through data-driven insights. Their expertise spans multi-country studies, utilizing both primary data collection and secondary electronic health record databases. In 2020, OXON was acquired by Envision Pharma Group, integrating its capabilities into a broader suite of medical affairs and evidence-generation services. The company remains a key player in the European RWE landscape, supporting the lifecycle of innovative therapies and medical devices.